Portal Chicago portfolio company, Grove Biopharma, announces $30M Series A!

Our Chicago-based portfolio company, Grove Biopharma, announced today a monster $30M Series A round to develop therapeutics against previously undruggable targets in oncology, neurodegenerative, and other diseases.